Sinonasal Mucosal Melanoma: Symptoms, Causes, and Treatment

Sinonasal mucosal melanoma is a rare and aggressive cancer that arises from pigment-producing cells lining the inside of the nasal cavity and sinuses. It accounts for a tiny fraction of all melanomas but behaves far worse than the skin variety most people associate with the word. The disease tends to announce itself through everyday nasal symptoms like nosebleeds and stuffiness, which is part of why it is often caught late and at an advanced stage.

What Sinonasal Mucosal Melanoma Feels Like

The two hallmark symptoms are nosebleeds and nasal obstruction, typically on one side of the nose.¹ Because those symptoms overlap with allergies, sinus infections, and polyps, people often wait weeks or months before seeing a doctor. In one reported case, a 43-year-old woman experienced eight weeks of recurrent one-sided nosebleeds before clinicians identified a friable mass in her nasal passage.² Headache, facial pain, and swelling develop as the tumor grows, and some patients notice changes in their sense of smell or tearing from one eye. A Chinese cohort of 36 patients confirmed that nosebleeds, nasal blockage, headache, and facial pain were the most common initial complaints.³

What makes this cancer especially tricky is that the symptoms tend to develop late and remain vague. There is no reliable early warning sign. The nasal cavity is a hidden space, so a small tumor can grow for some time before it triggers enough bleeding or blockage to prompt a visit to the doctor. By the time most patients are diagnosed, the tumor is already locally advanced. In that same Chinese cohort, nearly four in five patients already had stage IV disease at diagnosis.³

Who Develops This Cancer

Sinonasal mucosal melanoma is genuinely rare. Population studies place the incidence at roughly 0.05 per 100,000 people per year.⁴ The disease disproportionately affects older adults; about 70 percent of cases occur in people aged 65 and older, both in Europe and the United States.⁵ More than 90 percent of patients are over 50.⁴ Women are slightly more affected than men, with females making up roughly 55 to 56 percent of cases across large registries.⁵ In U.S. data, more than 90 percent of patients were Caucasian.⁴

As for where exactly in the sinonasal tract the tumor grows, the nasal cavity itself is the dominant site, accounting for about 65 to 83 percent of cases depending on the registry, followed by the maxillary sinus at roughly 8 to 16 percent.⁵ The nasal septum and lateral nasal wall are common subsites. Tumors buried deeper in the sinuses tend to be discovered even later, simply because they are harder to see during a routine exam.

Why UV Exposure Is Not the Cause

People often assume all melanomas are caused by sun damage, but sinonasal mucosal melanoma breaks that rule entirely. The lining of the nasal cavity and sinuses never sees sunlight. Multiple reviews confirm that UV exposure is not an apparent risk factor for mucosal melanoma.⁶ This makes it fundamentally different from the cutaneous melanoma that dominates public health campaigns.

What actually triggers melanocytes in the nasal mucosa to become malignant remains poorly understood. No strong environmental risk factor has been established. Formaldehyde exposure and tobacco smoking have been loosely proposed, but the evidence is thin and inconsistent. The honest answer is that, for most patients, there is no identifiable cause. This lack of a clear trigger is one reason prevention campaigns for this cancer do not exist in the way they do for skin melanoma.

A Different Molecular Profile

Because the cause is different, the genetic mutations driving this cancer also look different from cutaneous melanoma. In skin melanoma, BRAF mutations are common and form the basis for targeted drugs. In sinonasal mucosal melanoma, BRAF mutations are uncommon. A study of 56 tumors found BRAF mutations in just 4 percent of cases, with KIT mutations also at 4 percent and NRAS mutations at 14 percent.⁷ A separate cohort of 66 patients found somewhat higher rates overall — NRAS mutations in 30 percent, BRAF in 8 percent, and KIT in 5 percent — but the pattern was the same: most tumors lacked any of the common targetable mutations.⁸

This molecular profile is important for treatment decisions. The low rate of BRAF mutations means the drugs that have transformed outcomes in advanced skin melanoma, like vemurafenib and dabrafenib, are rarely useful here.⁹ The somewhat more common NRAS and KIT mutations suggest that strategies targeting those pathways may hold more promise, though the evidence remains early. Roughly 60 to 80 percent of sinonasal mucosal melanomas carry none of these three mutations, leaving a large group of patients without a clear molecular target.

How the Diagnosis Is Made

A suspicious mass in the nasal cavity spotted during an endoscopic exam usually prompts a biopsy, and the pathology workup is critical because sinonasal mucosal melanoma is a master of disguise. Only about 58 percent of these tumors show visible melanin pigment; the rest are amelanotic, meaning they lack the dark coloring people associate with melanoma.¹⁰ That can lead pathologists down the wrong path initially. The cells themselves vary in shape, sometimes mimicking other cancers entirely.¹¹

Special staining helps sort things out, but even standard markers can mislead. S100 protein, long used as a go-to screening marker for melanoma, turns out to be unreliable in sinonasal cases. A study of 23 tumors found that 5 were completely negative for S100 and another 7 showed only weak or patchy staining. In contrast, every single case was strongly positive for SOX10, making it a far more dependable marker.¹² Another emerging marker, PRAME, showed diffuse staining in 89 percent of cases in a 90-tumor study.¹⁰ These newer markers are increasingly important for avoiding a missed or delayed diagnosis.

MRI plays a role beyond biopsy. When the tumor contains melanin, MRI produces a characteristic pattern — high signal on T1-weighted images without contrast and low signal on T2-weighted images — that can raise the suspicion for melanoma before the pathology report comes back.¹³ MRI is also essential for mapping how far the tumor extends, particularly whether it invades the orbit or skull base, which directly affects surgical planning.

Surgery Is the Foundation

For tumors that can be removed, surgery is the primary treatment. The big debate over the past two decades has been whether endoscopic surgery, working through the nostrils with a camera, provides the same cancer control as traditional open approaches that may involve cutting through the facial bones or skull base. The accumulated evidence suggests the answer is yes, at least for tumors that can be fully removed either way. A study of 72 patients found no difference in overall survival between the two approaches, with the absolute three-year difference in survival sitting within a range that could easily be due to chance.¹⁴ A smaller comparison similarly showed comparable overall survival and disease-free survival between open and endoscopic resection.¹⁵

A systematic review and meta-analysis of sinonasal malignancies more broadly found that when the data was pooled with regression analysis, endoscopic resection actually showed a survival advantage over open surgery.¹⁶ That finding likely reflects patient selection — surgeons choose the endoscopic approach for tumors that are more accessible and less extensive — rather than a true benefit of the camera itself. Still, when the tumor anatomy allows it, endoscopic surgery spares patients the morbidity of an open procedure without compromising cancer outcomes.

Quality of life is meaningfully different between the two approaches. Patients who undergo open resection report worse general quality of life compared with those treated endoscopically, even after adjusting for the size of the tumor.¹⁷ Involvement of certain deep structures, like the space behind the cheekbone known as the pterygopalatine fossa, was associated with worse quality-of-life scores regardless of approach. Adjuvant radiation also took a measurable toll on disease-specific quality of life.¹⁷

The Role of Radiation

Most patients receive radiation after surgery. The goal is to reduce the chance of the tumor coming back in the area where it grew, because local recurrence is stubbornly common. Standard photon radiation is the most widely available option, but particle-based therapies have generated interest. Carbon-ion radiation therapy, available primarily in Japan, reported two-year local control rates around 84 percent and five-year local control around 72 percent in a multicenter study of head and neck mucosal melanomas.¹⁸ Proton beam therapy, more accessible in the West, showed encouraging early results in a small series: one-year local control of 88 percent with no severe late side effects.¹⁹

These particle therapies deposit their energy more precisely than conventional X-ray beams, which matters when the tumor bed sits millimeters from the brain, optic nerves, and eyes. Whether the local control advantage translates into longer survival remains uncertain, partly because distant metastases remain the dominant killer regardless of how well the primary site is controlled.

Immunotherapy and Systemic Treatment

Immune checkpoint inhibitors have transformed outcomes in advanced skin melanoma, but their effectiveness in mucosal melanoma has been more modest.²⁰ Part of the problem is that mucosal melanomas tend to have a low mutational burden, meaning fewer abnormal proteins for the immune system to recognize and attack. The tumor microenvironment is also immunosuppressive, which blunts the effect of drugs designed to unleash the immune response.

Combination strategies are being explored. A trial using the anti-PD-1 drug toripalimab combined with axitinib, an antiangiogenic agent that starves tumors of their blood supply, achieved a pathologic response in about a third of patients with resectable mucosal melanoma. Four of the 24 patients had complete pathologic responses, meaning no viable tumor was found in the surgical specimen.²¹ The combination was tolerable, with about a quarter of patients experiencing serious side effects but no treatment-related deaths.

Meanwhile, neoadjuvant immunotherapy with ipilimumab and nivolumab specifically for sinonasal mucosal melanoma has been tested at a single institution. The overall response rate was about 24 percent, and the patients who did respond had dramatically better outcomes, with two-year progression-free survival of 100 percent versus 15 percent for nonresponders.²² The challenge is that three-quarters of patients did not respond. A clinical trial called PRISM is now testing whether adding preoperative radiation to neoadjuvant immunotherapy can push that response rate higher.²³

Recurrence Patterns and What They Mean

Even with aggressive treatment, recurrence is the norm rather than the exception. A large meta-analysis found that the five-year freedom from local recurrence was only about 42 percent, and five-year freedom from distant metastasis was around 45 percent.²⁴ The most common sites for distant spread are the lungs, liver, bone, and brain. Regional lymph node recurrence, by contrast, is relatively uncommon, with five-year regional recurrence-free survival above 80 percent.²⁴

Distant metastasis is the predominant mode of failure.²⁵ In one institutional series, the median time to distant recurrence was about 12 months, compared with over three and a half years for locoregional recurrence. This imbalance explains why improving local control with better surgery or radiation, while worthwhile, has not dramatically changed overall survival. The disease tends to escape to distant organs before or shortly after local treatment is complete.

Survival and Prognostic Factors

Five-year overall survival for sinonasal mucosal melanoma hovers in the range of 20 to 45 percent across studies, depending on how advanced the disease is at diagnosis and how the cohort is selected. A staging comparison study found five-year overall survival of about 50 percent for stage III disease, dropping to roughly 18 percent for stage IVA and zero for stage IVB under the AJCC system.²⁶ These numbers underscore how much the stage at diagnosis matters.

Interestingly, mutation status does not appear to predict survival clearly. In one cohort, the five-year overall survival was 43 percent in patients whose tumors carried a mutation and 37 percent in those without, a difference that was not statistically meaningful.⁸ A separate single-center study likewise found that KIT expression did not significantly affect survival.²⁷ Researchers are looking at other biomarkers; one study identified high expression of a protein called TRIM27 as a predictor of worse overall survival, disease-free survival, and higher rates of distant metastasis.²⁸ That kind of finding could eventually help doctors identify patients most at risk for aggressive disease and tailor treatment accordingly.

Why Dogs May Help Advance Treatment

One of the more unexpected avenues of research involves canine melanoma. Dogs naturally develop mucosal melanoma, particularly in the mouth, at rates far higher than humans. Their tumors share key biological features with human mucosal melanomas, including low mutational burden, extensive structural chromosomal changes, and a heavily immunosuppressive tumor environment.²⁹ Recent transcriptomic work has shown that human and canine oronasal mucosal melanomas share conserved molecular subtypes, meaning the biology is similar enough that findings in dogs could meaningfully inform human clinical trial design.³⁰

Because mucosal melanoma is so rare in humans, recruiting enough patients for large clinical trials is painfully slow. Dogs with naturally occurring melanoma offer a much larger patient pool, develop tumors in immunocompetent hosts rather than laboratory conditions, and can be treated with the same classes of drugs in veterinary settings. The hope is that this comparative oncology approach can accelerate the testing of new therapies, particularly immunotherapy combinations, in a way that benefits both species.³¹